Form 4: GeneDx Holdings Corp. CEO Katherine Stueland Reports Stock Transactions

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the acquisition and disposition of Class A Common Stock related to restricted stock units.

Summary

• Katherine Stueland, the CEO of GeneDx Holdings Corp., filed a Form 4 detailing changes in her beneficial ownership of the company's stock.
• On July 29, 2024, she acquired 3,874 shares of Class A Common Stock upon the vesting of restricted stock units (RSUs) at a price of $0.
• Simultaneously, she sold 2,154 shares of Class A Common Stock at $33.54 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Stueland directly owns 92,550 shares of Class A Common Stock and 27,118 restricted stock units.
• The RSUs vest in quarterly installments, contingent upon her continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock-based compensation and tax obligations. There's no indication of unusual or concerning activity.

Positives

• The vesting of RSUs indicates a continued alignment of the CEO's interests with the company's performance.
• The 'sell to cover' transaction ensures tax obligations are met without requiring additional capital from the CEO.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing is typical for executives receiving stock-based compensation.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider trading activities.

Key Dates